(Q26800611)

title

Adoptive T-cell therapy for cancer: The era of engineered T cells (English)

0 references

author

Maria Chiara Bonini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anna Mondino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

14 June 2020

author name string

Chiara Bonini

series ordinal

1

0 references

language of work or name

English

0 references

publication date

September 2015

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

2457-2469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

Exploiting the curative potential of adoptive T-cell therapy for cancer

14 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Experts' considerations on HLA-haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Posttransplantation vaccination: concepts today and on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Improving the safety of cell therapy with the TK-suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Engineered T cells for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Design and development of therapies using chimeric antigen receptor-expressing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Hematopoietic stem cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Re-adapting T cells for cancer therapy: from mouse models to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Designing chimeric antigen receptors to effectively and safely target tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Chimeric antigen receptor T cells for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Use of TK-cells in haploidentical hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Improving the safety of cell therapy products by suicide gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Targeting cancer-specific mutations by T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

High-throughput identification of antigen-specific TCRs by TCR gene capture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Survivin-specific T cell receptor targets tumor but not T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

TCR repertoires of intratumoral T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Molecular regulation of effector and memory T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

A human memory T cell subset with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

A novel self-lipid antigen targets human T cells against CD1c(+) leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

SHP-1 phosphatase activity counteracts increased T cell receptor affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Genetic modification of cytotoxic T lymphocytes to express cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

T cell metabolic fitness in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-2: the first effective immunotherapy for human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Won't you come on in? How to favor lymphocyte infiltration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Optogenetic control of chemokine receptor signal and T-cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Concomitant Tumor and Minor Histocompatibility Antigen–Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

inferred from DOI database lookup

7 January 2021

based on heuristic

A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201545552

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/EJI.201545552

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202766%20AND%20SRC:MED&resulttype=core&format=json

release_wmsuous24zbhpb4gs5stn2uqda

14 June 2020

Fatcat ID

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017